ROCKET-AF Heart Failure Subgroup Risk Index
Patient characteristics
Complete all categorical fields. Creatinine may be left blank if unavailable.
About this experimental index
ROCKET-AF was a randomized trial comparing rivaroxaban with warfarin in patients with nonvalvular atrial fibrillation at increased risk of stroke. A subsequent analysis examined efficacy and safety outcomes among participants with heart failure.
This page implements a proposed educational composite using selected patient characteristics. The assigned weights were not derived from a published, validated ROCKET-AF heart-failure point score, and the total has not been shown to predict a specific probability of stroke, systemic embolism, bleeding, or death.
Proposed point allocation
| Criterion | Definition in this tool | Points |
|---|---|---|
| Age | ≥75 years | +1 |
| Prior stroke/TIA | History present | +2 |
| HF severity | EF <40% or NYHA III–IV | +1 |
| Creatinine | ≥1.5 mg/dL | +1 |
| Diabetes | History present | +1 |
| Hypertension | History present | +1 |
| Vascular disease | Prior MI or PAD | +1 |
| AF type | Persistent or permanent | +1 |
Clinical interpretation
Do not interpret the numerical total as a validated risk estimate. For stroke prevention decisions in atrial fibrillation, use a guideline-recommended, validated risk assessment approach and individual clinical evaluation. This tool does not assess bleeding risk or determine anticoagulant choice or dose.
References
New England Journal of Medicine. 2011;365:883–891.
Circulation: Heart Failure. 2013;6(4):740–747.
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.